Form 4: Akari Therapeutics CFO Acquires and Disposes of Shares in Company

Akari Therapeutics CFO, Torsten Hombeck, engaged in a transaction involving the acquisition and disposal of 200 American Depository Shares (ADS) on January 10, 2025.

Summary

• Torsten Hombeck, the CFO of Akari Therapeutics Plc, reported a transaction involving the company's American Depository Shares (ADS).
• On January 10, 2025, Mr. Hombeck acquired 200 ADS at a price of $1.22 per ADS.
• Simultaneously, Mr. Hombeck disposed of 200 ADS.
• Each ADS represents 2,000 ordinary shares of Akari Therapeutics.

Sentiment

Score: 5

Explanation: The document is a neutral report of a routine insider transaction, with no indication of positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting transactions in their company's securities. It is a routine disclosure and does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies, particularly in the biotech sector where insider trading is closely monitored.
• Similar filings are routinely made by executives at companies like Amgen, Gilead Sciences, and Biogen when they engage in transactions involving their company's stock.
• The transaction size of 200 ADS is relatively small compared to some insider transactions, which can involve thousands or millions of shares.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a routine insider transaction.

Key Dates

Keywords

Akari Therapeutics, ADS, American Depository Shares, Torsten Hombeck, CFO, Share Transaction, SEC Form 4